Abstract
The macrolide antibiotics azithromycin, roxithromycin and spiramycin were examined in parallel for in vivo activity againstToxoplasma gondii. Azithromycin was considerably more active in protecting mice against death due to acute toxoplasmosis even when the other two antibiotics were used at twice its dose. The higher activity of azithromycin prompted a further examination of its activity against five different strains ofToxoplasma gondii, including two isolated from patients with AIDS. Although variable degrees of protection against death were noted, treatment with 200 mg/kg/day for ten days was sufficient to promote survival of 100 % of mice infected with inocula as high as 1 × 105 tachyzoites ofToxoplasma gondii. 90 % of mice inoculated with 1 × 105 tachyzoites of strain MO, isolated from an AIDS patient, and treated orally with 200 mg/kg/day for ten days survived the infection whereas only 40 % of mice infected with the same inoculum of the SOU strain, also isolated from an AIDS patient, survived. Tissue concentrations of azithromycin were examined in treated infected and non-infected mice. In both groups of mice azithromycin attained high concentrations in liver, spleen and heart, which exceeded concurrent serum levels by 25- to 200-fold. The concentrations in the brain were almost tenfold higher than the concentrations in serum after treatment with 200 mg/kg/day for ten days. Moreover, the concentrations in brains of infected mice were approximately two-fold higher than in brains of non-infected mice.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Araujo FG, Remington JS: Toxoplasmosis in immunocompromised patients. European Journal of Clinical Microbiology and Infectious Diseases 1987, 6: 1–2.
Mills J:Pneumocystis carinii andToxoplasma gondii infections in patients with AIDS. Review of Infectious Diseases 1986, 8: 1001–1011.
Remington JS, Desmonts G: Toxoplasmosis. In: Remington JS, Klein JO (ed): Infectious Diseases of the fetus and newborn infants. W.B. Saunders, Philadelphia, 1990, p. 89–195.
Eyles DE, Coleman M: Synergistic effect of sulfadiazine and daraprin against experimental toxoplasmosis in the mouse. Antibiotics and Chemotherapy 1953, 3: 483–490.
Brooks RG, Remington JS, Luft BJ: Drugs used in the treatment of toxoplasmosis. In: Peterson PK, Verhoef J (ed): The Antimicrobial Agents Annual. Volume 2. Elsevier, Amsterdam, 1987, p. 297–306.
Israelski DM, Remington JS: Toxoplasmic encephalitis in patients with AIDS. Infectious Diseases Clinics of North America 1988, 2: 429–445.
Haverkos HW: Toxoplasmic encephalitis study group. Assessment of therapy for toxoplasmic encephalitis. American Journal of Medicine 1987, 82: 907–914.
Luft BJ: In vivo and in vitro activity of roxithromycin againstToxoplasma gondii in mice. European Journal of Clinical Microbiology and Infectious Diseases 1987, 6: 479–481.
Araujo FG, Guptill DR, Remington JS: Azithromycin: a macrolide antibiotic with potent activity againstToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 755–757.
Chang HR, Pechère JC: In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62, 993], and A-56268) onToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 524–529.
Hofflin JM, Remington JS: In vivo synergism of Roxithromycin (RU 965) and interferon againstToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1987, 31: 346–348.
Suzuki Y, Conley FK, Remington JS: Differences in virulence and development of encephalitis during chronic infection vary with the strain ofToxoplasma gondii. Journal of Infectious Diseases 1989, 159: 790–794.
Sabin AB: Toxoplasmic encephalitis in children Journal of the American Medical Association 1941, 116: 801–807.
Jacobs L, Melton ML: Toxoplasmosis in chickens. Journal of Parasitology 1966, 52: 1158–1162.
Jacobs L, Remington JS, Melton ML: A survey of meat samples from swine, cattle and sheep for the presence of encysted toxoplasma. Journal of Parasitology 1960, 46: 23–28.
Suzuki Y, Remington JS: A method for obtaining large numbers of trophozoites of avirulent strains ofToxoplasma gondii using an antibody to interferon gamma. Journal of Parasitology 1989, 75: 174–176.
Sabin AB, Feldman HA: Dyes as microchemical indicators of a new immunity phenomenon affecting a protozoan parasite(Toxoplasma). Science 1948, 108: 660–663.
Snedecor G, Cochran W: Stastical methods. Iowa State University Press, Ames, IA, 1980.
Shepard RM, Duthu GS, Ferraina RA, Mullins MA: High-performance liquid chromatographic assay with electro chemical detection for azithromycin in serum and tissues. Journal of Chromatography 1991, 565: 321–337.
Chan J, Luft BJ: Activity of roxithromycin (RU28965), a macrolide, againstToxoplasma gondii infection in mice. Antimicrobial Agents and Chemotherapy 1986, 30: 323–324.
Garin JP, Eyles DE: Le traitement de la toxoplasmose experimentale de la souris par la spiramycine. Presse Medicale 1958, 66: 957–958.
Mas Bakal P, Intveld N: Postponed spiramycin treatment of acute toxoplasmosis in white mice. Tropical and Geographical Medicine 1965, 17: 254–260.
Garin JP, Pellerat J, Maillard Mme: Bases theoriques de la prevention par la spiramycine de la toxoplasmose congenitale chez la femme enceinte. Presse Medicale 1968, 76: 2266.
Ware PL, Kasper L: Strain specific antigens ofToxoplasma gondii. Infection and Immunity 1987, 55: 778–783.
Menninger JR, Otto DP: Erythromycin carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrobial Agents and Chemotherapy 1982, 21: 811–818.
Gladue RP, Bright GM, Isaacson RE, Newborg MF: In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 1989, 33: 277–282.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Araujo, F.G., Shepard, R.M. & Remington, J.S. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin againstToxoplasma gondii . Eur. J. Clin. Microbiol. Infect. Dis. 10, 519–524 (1991). https://doi.org/10.1007/BF01963942
Issue Date:
DOI: https://doi.org/10.1007/BF01963942